NO20024321L - Fremgangsmate for fremstilling av krystallinsk form I av kabergolin - Google Patents

Fremgangsmate for fremstilling av krystallinsk form I av kabergolin

Info

Publication number
NO20024321L
NO20024321L NO20024321A NO20024321A NO20024321L NO 20024321 L NO20024321 L NO 20024321L NO 20024321 A NO20024321 A NO 20024321A NO 20024321 A NO20024321 A NO 20024321A NO 20024321 L NO20024321 L NO 20024321L
Authority
NO
Norway
Prior art keywords
cabergoline
crystalline form
preparation
toluene
recovery
Prior art date
Application number
NO20024321A
Other languages
English (en)
Norwegian (no)
Other versions
NO20024321D0 (no
Inventor
Attilio Tomasi
Mario Ungari
Giafranco Pallanza
Stefania Magenes
Giuliano Ramella
Original Assignee
Pharmacia Italia Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9888433&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20024321(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pharmacia Italia Spa filed Critical Pharmacia Italia Spa
Publication of NO20024321D0 publication Critical patent/NO20024321D0/no
Publication of NO20024321L publication Critical patent/NO20024321L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D457/00—Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula:, e.g. lysergic acid
    • C07D457/04—Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula:, e.g. lysergic acid with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 8
    • C07D457/06—Lysergic acid amides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D457/00—Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula:, e.g. lysergic acid
    • C07D457/04—Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula:, e.g. lysergic acid with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 8
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/16—Masculine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Psychology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NO20024321A 2000-03-24 2002-09-10 Fremgangsmate for fremstilling av krystallinsk form I av kabergolin NO20024321L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0007308.0A GB0007308D0 (en) 2000-03-24 2000-03-24 Process for preparing crystalline form | of cabergoline
PCT/EP2001/003099 WO2001070740A1 (en) 2000-03-24 2001-03-19 Process for preparing crystalline form i of cabergoline

Publications (2)

Publication Number Publication Date
NO20024321D0 NO20024321D0 (no) 2002-09-10
NO20024321L true NO20024321L (no) 2002-09-10

Family

ID=9888433

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20024321A NO20024321L (no) 2000-03-24 2002-09-10 Fremgangsmate for fremstilling av krystallinsk form I av kabergolin

Country Status (31)

Country Link
US (2) US6727363B2 (de)
EP (1) EP1272489B1 (de)
JP (1) JP4184666B2 (de)
KR (1) KR100827558B1 (de)
CN (1) CN1188412C (de)
AR (1) AR032449A1 (de)
AT (1) ATE250601T1 (de)
AU (2) AU780747B2 (de)
BR (1) BR0109507A (de)
CA (1) CA2402836A1 (de)
CZ (1) CZ20023176A3 (de)
DE (1) DE60100858T2 (de)
DK (1) DK1272489T3 (de)
EA (1) EA005928B1 (de)
EE (1) EE05088B1 (de)
ES (1) ES2208602T3 (de)
GB (1) GB0007308D0 (de)
HK (1) HK1052348B (de)
HU (1) HUP0300591A3 (de)
IL (2) IL150985A0 (de)
MX (1) MXPA02009283A (de)
MY (1) MY134189A (de)
NO (1) NO20024321L (de)
NZ (1) NZ521316A (de)
PE (1) PE20011140A1 (de)
PL (1) PL358253A1 (de)
PT (1) PT1272489E (de)
SI (1) SI1272489T1 (de)
SK (1) SK13582002A3 (de)
WO (1) WO2001070740A1 (de)
ZA (1) ZA200206045B (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0007307D0 (en) * 2000-03-24 2000-05-17 Pharmacia & Upjohn Spa Crystalline form || of cabergoline
GB0007308D0 (en) 2000-03-24 2000-05-17 Pharmacia & Upjohn Spa Process for preparing crystalline form | of cabergoline
DE10043321B4 (de) * 2000-08-24 2005-07-28 Neurobiotec Gmbh Verwendung eines transdermalen therapeutischen Systems zur Behandlung der Parkinsonschen Krankheit, zur Behandlung und Prävention des prämenstruellen Syndroms und zur Lactationshemmung
DE10053397A1 (de) * 2000-10-20 2002-05-02 Schering Ag Verwendung eines dopaminergen Wirkstoffes zur Behandlung von dopaminerg behandelbaren Erkrankungen
DE10064453A1 (de) * 2000-12-16 2002-07-04 Schering Ag Verwendung eines dopaminergen Wirkstoffes zur Behandlung von dopaminerg behandelbaren Erkrankungen
AU2003218753A1 (en) * 2002-03-15 2003-09-29 Pharmacia Corporation Process for preparing crystalline form i of cabergoline
CN1642953A (zh) * 2002-03-15 2005-07-20 法玛西雅公司 制备卡麦角林晶型i的方法
IL155545A (en) * 2003-04-21 2009-12-24 Finetech Pharmaceutical Ltd Solvate form of cabergoline
AU2004238833A1 (en) * 2003-05-08 2004-11-25 Ivax Pharmaceuticals S.R.O. Polymorphs of cabergoline
GB0409785D0 (en) * 2004-04-30 2004-06-09 Resolution Chemicals Ltd Preparation of cabergoline
GB0515430D0 (en) * 2005-07-27 2005-08-31 Resolution Chemicals Ltd Preparation of cabergoline
US7339060B2 (en) 2005-03-23 2008-03-04 Resolution Chemicals, Ltd. Preparation of cabergoline
GB0505965D0 (en) 2005-03-23 2005-04-27 Resolution Chemicals Ltd Preparation of cabergoline
EP1925616A1 (de) * 2006-10-26 2008-05-28 LEK Pharmaceuticals D.D. Verfahren zur Herstellung kristalliner Formen des Cabergolins via stabile Solvate des Cabergolins
EP1953157A1 (de) 2007-01-31 2008-08-06 LEK Pharmaceuticals D.D. Neue Kristallform von Cabergolin
EP2185169A2 (de) * 2007-08-29 2010-05-19 Max Zeller Söhne AG Verwendung von extrakten von vitex agnus castus zur herstellung eines medikaments
EP4074552B1 (de) * 2021-04-16 2024-04-03 Thermo King LLC Elektrische verbindungseinheit

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3019322A1 (de) 1980-05-21 1981-12-03 Merck Patent Gmbh, 6100 Darmstadt Psychopharmakon sowie verwendung von adenosinderivaten
US4526892A (en) * 1981-03-03 1985-07-02 Farmitalia Carlo Erba, S.P.A. Dimethylaminoalkyl-3-(ergoline-8'βcarbonyl)-ureas
GB2103603B (en) * 1981-08-11 1985-04-11 Erba Farmitalia Ergoline derivatives
GB9205439D0 (en) 1992-03-12 1992-04-22 Erba Carlo Spa Process for the synthesis of ergoline derivatives
JPH08502759A (ja) 1993-08-18 1996-03-26 アルコン ラボラトリーズ，インコーポレイテッド 緑内障治療用のエルゴリン誘導体の使用
US20020010197A1 (en) 1998-01-13 2002-01-24 John Dixon Pharmaceutical compositions comprising a compound having dopamine (d2) receptor agonist activity and a compound (b) having beta2-adrenoreceptor agonist activity
CZ297284B6 (cs) 1998-03-27 2006-10-11 Pharmacia & Upjohn Company Farmaceutiký prostredek pro lécbu syndromu neklidných nohou
GB0007309D0 (en) 2000-03-24 2000-05-17 Pharmacia & Upjohn Spa Crystalline form V|| of cabergoline
GB0007308D0 (en) * 2000-03-24 2000-05-17 Pharmacia & Upjohn Spa Process for preparing crystalline form | of cabergoline
GB0007307D0 (en) 2000-03-24 2000-05-17 Pharmacia & Upjohn Spa Crystalline form || of cabergoline

Also Published As

Publication number Publication date
ZA200206045B (en) 2003-07-29
AU6211001A (en) 2001-10-03
EA005928B1 (ru) 2005-08-25
MXPA02009283A (es) 2003-03-12
BR0109507A (pt) 2002-12-10
CA2402836A1 (en) 2001-09-27
AU2005203071A1 (en) 2005-08-11
CN1419554A (zh) 2003-05-21
HK1052348A1 (en) 2003-09-11
HK1052348B (zh) 2005-09-16
CN1188412C (zh) 2005-02-09
IL150985A0 (en) 2003-02-12
HUP0300591A2 (hu) 2003-07-28
PE20011140A1 (es) 2001-11-01
CZ20023176A3 (cs) 2003-02-12
HUP0300591A3 (en) 2009-01-28
NO20024321D0 (no) 2002-09-10
JP2003528100A (ja) 2003-09-24
PL358253A1 (en) 2004-08-09
AR032449A1 (es) 2003-11-12
DE60100858D1 (de) 2003-10-30
DE60100858T2 (de) 2004-07-29
EA200201016A1 (ru) 2003-02-27
EP1272489A1 (de) 2003-01-08
MY134189A (en) 2007-11-30
PT1272489E (pt) 2004-02-27
KR20020081587A (ko) 2002-10-28
US20030149067A1 (en) 2003-08-07
GB0007308D0 (en) 2000-05-17
SK13582002A3 (sk) 2003-04-01
EE05088B1 (et) 2008-10-15
DK1272489T3 (da) 2003-12-15
KR100827558B1 (ko) 2008-05-07
NZ521316A (en) 2004-05-28
US6953854B2 (en) 2005-10-11
AU2005203071B2 (en) 2007-10-18
US6727363B2 (en) 2004-04-27
EE200200545A (et) 2004-04-15
US20040092744A1 (en) 2004-05-13
WO2001070740A1 (en) 2001-09-27
IL150985A (en) 2007-03-08
ATE250601T1 (de) 2003-10-15
EP1272489B1 (de) 2003-09-24
ES2208602T3 (es) 2004-06-16
SI1272489T1 (en) 2004-02-29
AU780747B2 (en) 2005-04-14
JP4184666B2 (ja) 2008-11-19

Similar Documents

Publication Publication Date Title
NO20024321L (no) Fremgangsmate for fremstilling av krystallinsk form I av kabergolin
MXPA03007853A (es) Metodo para la sintesis de 2',3'-didesoxi-2',3'-dideshidronucleosidos.
NO20083446L (no) Fenyl-piperazinderivater som serotonin-reopptaksinhibitorer
MXPA02012795A (es) Carvedilol.
LV12735A (en) Manufacture and pharmaceutical compositions thereof
NO992825L (no) Fremgangsmåter for fremstilling av 9,11-epoksysteroider og derved brukbare mellomprodukter
ZA200202568B (en) Process for the synthesis of silicoaluminophosphate molecular sieves.
MX9707706A (es) Compuestos intermediarios novedosos y proceso para la manufactura de derivados de la camptotecina (cpt-11) y compuestos relacionados.
NO20085417L (no) Krystallinske former av 11beta-(4-acetylfenyl)-20,20,21,21,21-pentafluor-17-hydroksy-19-nor-17alfa-pregna-4,9-dien-3-on
EP0029265B1 (de) Verfahren zur Herstellung von Azetidinderivaten, diese enthaltende Zusammensetzungen mit sterilisierender Wirkung für männliche Pflanzenteile, deren Verwendung zur Sterilisation männlicher Teile in Pflanzen, Verfahren zur Herstellung von F1-Hybridsamen und bestimmte Azetidinderivate
NO20050720L (no) Krystallformer av olanzapin og fremgangsmate for deres fremstilling
YU24001A (sh) Nova kristalna modifikacija torasemida
WO2002044194A1 (fr) Derives d'acide l-nucleique et procedes de synthese correspondants
DK1133511T3 (da) Hidtil ukendte mellemprodukter, fremgangsmåde til fremstilling af makrolidantibiotikum derudfra
NO20071253L (no) Fremgangsmate for syntese av C-2, C-3 substituerte N-alkylerte indoler anvendbare som CPLA2-inhibitorer.
IL141212A0 (en) Process for the synthesis of (1h)-benzo [c] quinolizin-3-one derivatives
ATE299878T1 (de) Verfahren zur herstellung von azacycloalkanoylaminothiazolen
RS77704A (en) Process for preparing crystalline form 1 of cabergoline
YU3099A (sh) Novi derivati eritromicina, postupak za njihovo dobijanje i njihova primena
NO20020183L (no) Fremgangsmåte for deacylering av lipodepsipeptider
WO2004069774A3 (en) Synthesis of 13c-labelled estrogen analogues
EA200201003A1 (ru) Аморфная модификация торасемида
HUP0200058A2 (hu) Eljárás N-(4-trifluor-metil-fenil)-5-metil-izoxazol-4-karboxamid kristályosítására
ATE354580T1 (de) Oleandomycin-derivate
FR2854402B1 (fr) Nouveau procede et intermediaires de preparation de composes 19-nor-steroides

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application